Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Hogarty

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Oncogene|March 29, 2006
BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastomaK C Goldsmith, X Liu, V Dam, et al.
Oncogene|August 29, 2007
Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplificationX Liu, P Mazanek, V Dam, et al.
Medical and Pediatric Oncology|December 7, 2000
Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomasM D Hogarty, X Liu, C Guo, et al.
Oncoimmunology|June 1, 2022
<i>TH-MYCN</i> tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapyK O McNerney, S Karageorgos, G M Ferry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastomaM A Grotzer, M D Hogarty, A J Janss, et al.
Medical and Pediatric Oncology|July 24, 2001
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastomaJ M Maris, C Guo, P S White, et al.
Oncogene|September 22, 1999
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomasC Guo, P S White, M J Weiss, et al.
Medical and Pediatric Oncology|December 7, 2000
Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13M J Weiss, C Guo, S Shusterman, et al.
Medical and Pediatric Oncology|July 24, 2001
Comprehensive analysis of chromosome 1p deletions in neuroblastomaJ M Maris, C Guo, D Blake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group studyJ M Maris, M J Weiss, C Guo, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Oncogene|March 29, 2006
BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastomaK C Goldsmith, X Liu, V Dam, et al.
Oncogene|August 29, 2007
Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplificationX Liu, P Mazanek, V Dam, et al.
Medical and Pediatric Oncology|December 7, 2000
Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomasM D Hogarty, X Liu, C Guo, et al.
Oncoimmunology|June 1, 2022
<i>TH-MYCN</i> tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapyK O McNerney, S Karageorgos, G M Ferry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastomaM A Grotzer, M D Hogarty, A J Janss, et al.
Medical and Pediatric Oncology|July 24, 2001
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastomaJ M Maris, C Guo, P S White, et al.
Oncogene|September 22, 1999
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomasC Guo, P S White, M J Weiss, et al.
Medical and Pediatric Oncology|December 7, 2000
Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13M J Weiss, C Guo, S Shusterman, et al.
Medical and Pediatric Oncology|July 24, 2001
Comprehensive analysis of chromosome 1p deletions in neuroblastomaJ M Maris, C Guo, D Blake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group studyJ M Maris, M J Weiss, C Guo, et al.
Pageof 3